Centessa Pharmaceuticals PLC

Change company Symbol lookup

Select an option...

CNTA Centessa Pharmaceuticals PLC

ZVSA Zyversa Therapeutics Inc

MYMD MyMD Pharmaceuticals Inc

$NQUSS302050EUR Nasdaq US Small Cap Open End and Mis

JOBY Joby Aviation Inc

RVLP RVL Pharmaceuticals PLC

PDO PIMCO Dynamic Income Opportunities Fund

BOCT Innovator U.S. Equity Buffer ETF™ October

BAC Bank of America Corp

YARIY Yara International ASA

Go

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

ADR Fees

American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees